SynthesisFrontiers in public health2022

Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials.

Yake Lou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.